Renaissance Technologies’s Arcturus Therapeutics ARCT Stock Holding History

Renaissance Technologies’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144K	Sell	21,400 -156,900	-88%	-$1.24M	﹤0.01%	2936
2026 Q1	$1.38M	Buy	178,300 +58,395	+49%	+$426K	﹤0.01%	2102
2025 Q4	$735K	Buy	+119,905	New	+$1.29M	﹤0.01%	2416
2024 Q1	–	Sell	-10,202	Closed	-$322K	–	3686
2023 Q4	$322K	Sell	10,202 -169,498	-94%	-$4.03M	﹤0.01%	2957
2023 Q3	$4.59M	Sell	179,700 -86,000	-32%	-$2.65M	0.01%	1355
2023 Q2	$7.62M	Buy	+265,700	New	+$7.23M	0.01%	1169
2022 Q1	–	Sell	-26,687	Closed	-$988K	–	4061
2021 Q4	$988K	Buy	+26,687	New	+$1.09M	﹤0.01%	2646
2021 Q3	–	Sell	-29,500	Closed	-$998K	–	3450
2021 Q2	$998K	Sell	29,500 -113,300	-79%	-$3.84M	﹤0.01%	2668
2021 Q1	$5.9M	Buy	+142,800	New	+$8.51M	0.01%	1555
2020 Q1	–	Sell	-23,300	Closed	-$253K	–	3427
2019 Q4	$253K	Sell	23,300 -9,200	-28%	-$96.3K	﹤0.01%	3119
2019 Q3	$334K	Buy	+32,500	New	+$351K	﹤0.01%	3004

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies's ARCT Position: Q2 2026 in Review

Renaissance Technologies reduced its Arcturus Therapeutics (ARCT) stake by 88% in Q2 2026, selling an estimated $1.24M and leaving 21,400 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Renaissance Technologies first reported a position in ARCT in Q3 2019 and has held it in 11 quarters since. The position peaked at $7.62M in Q2 2023. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Renaissance Technologies held 21,400 shares of Arcturus Therapeutics worth $144K as of Q2 2026.
Renaissance Technologies sold 156,900 Arcturus Therapeutics shares in Q2 2026, an estimated $1.24M.
Arcturus Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2936 holding.
Renaissance Technologies first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 11 quarters since.
Renaissance Technologies's Arcturus Therapeutics position peaked at $7.62M in Q2 2023.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.